Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Reaches New 52-Week Low at $9.33

Shares of Shionogi & Co., Ltd. (OTCMKTS:SGIOYGet Free Report) reached a new 52-week low on Monday . The company traded as low as $9.33 and last traded at $9.58, with a volume of 383951 shares changing hands. The stock had previously closed at $9.71.

Shionogi & Co., Ltd. Price Performance

The company has a quick ratio of 5.37, a current ratio of 5.86 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $11.34 billion, a PE ratio of 9.91, a price-to-earnings-growth ratio of 2.71 and a beta of 0.21. The firm’s 50 day simple moving average is $10.81 and its 200 day simple moving average is $11.74.

Shionogi & Co., Ltd. (OTCMKTS:SGIOYGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported $0.21 earnings per share for the quarter. Shionogi & Co., Ltd. had a net margin of 37.29% and a return on equity of 13.20%. The business had revenue of $662.08 million for the quarter. As a group, research analysts anticipate that Shionogi & Co., Ltd. will post 0.87 EPS for the current fiscal year.

About Shionogi & Co., Ltd.

(Get Free Report)

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

Featured Articles

Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.